SERB Pharmaceuticals buys European and MENA rights to Idefirix for €115m

SERB Pharmaceuticals has agreed to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) across the European Union, UK, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa from Hansa Biopharma for €115 million. The Brussels-headquartered specialty pharma group is paying €110 million upfront, with a further €5 million contingent on the European Medicines Agency accepting a filing for full approval of the product.

Idefirix is an IgG-cleaving enzyme derived from Streptococcus pyogenes that rapidly degrades donor-specific antibodies, enabling kidney transplantation in highly sensitised patients who would otherwise face a positive crossmatch against an available deceased donor. The drug carries conditional approval across the EU and UK, having been developed through the EMA's Priority Medicines (PRIME) scheme. An estimated 10–15% of the roughly 70,000 Europeans on end-stage renal disease waiting lists each year are considered highly sensitised, leaving many dependent on long-term dialysis for an indefinite period.

Deal structure and next steps

Under the terms of the agreement, SERB will assume responsibility for a long-term Post-Authorisation Efficacy Study (PAES) and an ongoing paediatric study once it becomes Marketing Authorisation Holder — a transfer the parties expect to initiate immediately after closing. Hansa has committed to supporting SERB through the EMA filing and review process once PAES topline data are reported. Completion is subject to customary conditions including foreign direct investment regulatory clearance, which the companies anticipate within 60 days.

Jeremie Urbain, Chairman of SERB Pharmaceuticals, said the company would "leverage its deep expertise, proven commercial execution and established platform across Europe and MENA to expand the reach and clinical impact of Idefirix."

The divestiture leaves Hansa free to focus on its US regulatory programme: the FDA accepted a Biologics Licence Application for imlifidase in February 2026 and has assigned a PDUFA action date of 19 December 2026. That US pathway, if successful, would transform imlifidase into a transatlantic product — albeit with the commercial burden of the European territory now transferred to SERB.

Market context and competitive landscape

The highly sensitised transplant population represents one of the more clearly defined rare-disease niches in renal medicine, and Idefirix currently sits without a direct approved competitor for the desensitisation indication in Europe. However, the field is not without broader pressure: apheresis-based desensitisation protocols and intravenous immunoglobulin regimens remain in clinical use at many transplant centres, and several academic groups are investigating complement inhibitors and next-generation antibody-depleting agents that could broaden the competitive picture over the medium term.

For SERB, the acquisition fits an established model of acquiring rights to approved or late-stage specialty medicines with unmet-need profiles, then extending their geographic reach through a commercial infrastructure that the company says now spans more than 100 countries. The MENA component is notable: kidney disease prevalence in several Gulf states is among the highest globally, and transplant programmes in Saudi Arabia and the UAE have been expanding capacity. Whether SERB can convert that infrastructure advantage into meaningful commercial penetration in markets where reimbursement pathways remain heterogeneous will be a key variable for investors to watch.

Rothschild & Co and Freshfields advised SERB on the transaction; Centerview Partners UK and Morgan Lewis advised Hansa.